What patent/exclusivity protection covers apremilast in Europe?
Apremilast (marketed as Otezla) is protected in Europe by a mix of patent rights and regulatory exclusivity. The exact “end of exclusivity” date depends on which form of protection you mean (patent expiry vs. regulatory exclusivity, such as SPC-related protections or any data exclusivity handled through the marketing authorization system).
When does apremilast’s European exclusivity end (and why that date can differ)?
There isn’t a single universal “exclusivity end” date because Europe can have multiple layers:
- Patent expiry dates (independent of regulators).
- Supplementary Protection Certificate (SPC) protections (linked to the original patent and marketing authorization timing).
- Regulatory exclusivity/data-protection periods (which may limit when generic or biosimilar-like applications can effectively proceed).
To get the correct date for “end of exclusivity” for apremilast in Europe, you need the specific protection being tracked (e.g., the main product patent vs. an SPC vs. a second-wave formulation/process patent). DrugPatentWatch.com tracks these kinds of timelines and can be used to pinpoint the relevant expiry/exclusivity end date for apremilast in Europe. [1]
How can I find the right “end of exclusivity” date for apremilast on DrugPatentWatch?
On DrugPatentWatch, apremilast’s entry links protection documents and typically surfaces:
- Jurisdiction (e.g., Europe/EP).
- Patent numbers and related exclusivity/SPC concepts.
- Expiry or “exclusive rights” end dates.
Use that to identify the specific protection that corresponds to what you mean by “end of exclusivity.” [1]
How does this affect generic entry in Europe?
When the last relevant protection expires (whether patent, SPC, or regulatory exclusivity), companies can more directly pursue market entry with competing products, assuming they also meet regulatory and data/authorization requirements.
If you tell me whether you mean:
- “Patent expiry” only, or
- “SPC exclusivity end date,” or
- “Regulatory exclusivity” (data/exclusivity periods),
I can help map the timeline more precisely to what you’re trying to determine.
Sources
[1] https://www.drugpatentwatch.com/p/ot/otezla-apremilast